PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer

Prescription Drug User Fee Act (PDUFA) date set for August 16, 2020. MADRID and DUBLIN, Feb. 17, 2020 -- (Healthcare Sales & Marketing Network) -- PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the U.S. Food and Drug Admi... Biopharmaceuticals, Oncology, FDA Jazz Pharmaceuticals, PharmaMar , lurbinectedin

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2045768

Source: HSMN NewsFeed - February 17, 2020 Category: Pharmaceuticals Source Type: news